BeiGene
BGNE

$162.54

0.45%

Market Cap: 17.2B

About: BeiGene Ltd is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. BeiGene's key cancer treatments are BRUKINSA (zanubrutinib), Bruton's tyrosine kinase (BTK) inhibitor, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody. In addition, it has a diverse pipeline of novel therapeutics focusing on a range of malignancies, including AML, MDS, multiple myeloma, lung, gastrointestinal, breast, and gynecologic cancers. The Company operates in one segment: pharmaceutical products and is primarily located in the U.S. and the PRC. Key revenue is generated from the U.S.

Employees: 10,000

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 8 analysts

0

News positive %

of 3 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

93% more repeat investments, than reductions

Existing positions increased: 85 | Existing positions reduced: 44

43% more funds holding in top 10

Funds holding in top 10: 7 [Q4 2023] → 10 (+3) [Q1 2024]

8% more call options, than puts

Call options by funds: $14.2M | Put options by funds: $13.2M

3% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 39

1% more funds holding

Funds holding: 196 [Q4 2023] → 197 (+1) [Q1 2024]

0.12% more ownership

Funds ownership: 3.59% [Q4 2023] → 3.71% (+0.12%) [Q1 2024]

10% less capital invested

Capital invested by funds: $8.1B [Q4 2023] → $7.26B (-$841M) [Q1 2024]

See Fund Rankings

Research analyst outlook

8 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$153

6%

downside

Avg. target

$210

29%

upside

High target

$345

112%

upside

8 analyst ratings

5 positive

63%

3 neutral

38%

0 negative

0%

B of A Securities David Li	6%downside $152.5	Neutral Maintained	9 Jul 2024
TD Cowen Yaron Werber	56%upside $254	Buy Maintained	9 May 2024
TD Cowen Yaron Werber	45%upside $236	Buy Maintained	24 Apr 2024
B of A Securities David Li	1%upside $164.3	Neutral Maintained	8 Apr 2024
Bernstein Rebecca Liang	1%downside $161	Market Perform Maintained	27 Mar 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about BGNE published over the past 30 days

MarketVector Indexes Licenses its flagship Ethereum Benchmark Rate to VanEck for ETHV, the pioneering Spot Ethereum ETF

FRANKFURT, Germany--(BUSINESS WIRE)--MarketVector IndexesTM (“MarketVector”) announces the licensing of the MarketVectorTM Ethereum Benchmark Rate (EBR) to VanEck. The firm today launched the VanEck Ethereum ETF (ETHV), a first-of-its-kind ETF that provides exposure to spot Ethereum in the US. MarketVectorTM Ethereum Benchmark Rate (EBR) is a robust tool for understanding the market value of Ethereum. The index methodology is designed with a focus on accuracy, reliability, and resilience agains.

MarketVector Indexes Licenses its flagship Ethereum Benchmark Rate to VanEck for ETHV, the pioneering Spot Ethereum ETF

BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World

HOPEWELL, N.J.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the opening of its flagship U.S. facility in Hopewell, N.J., at the Princeton West Innovation Campus, which houses state-of-the-art biologics manufacturing capabilities and a clinical research and development center that further bolster the Company's differentiated model as an oncology innovator. BeiGene has more than 30 molecules at clinical or commercial stage, a.

BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World

BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer

SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the Company through August to support the transition. “We are thrilled to welcome Aaron amid a transformational year for BeiGene as we became a top 15 global oncology innovat.

BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer

BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)

Brukinsa, a BTK inhibitor by BeiGene, shows strong revenue growth amidst ongoing patent litigation with AbbVie. BeiGene's financial health appears stable, with a favorable current ratio and a cash runway extending into 2026. I recommend buying BeiGene stock due to Brukinsa's robust growth potential and the company's lower valuation since last year.

BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)

BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024

SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, announced the presentation of new data from the SEQUOIA study of BRUKINSA® (zanubrutinib) today at the European Hematology Association 2024 Hybrid Congress (EHA2024) in Madrid, Spain in an oral session (Abstract S160). The presentation will feature data from arm D of SEQUOIA evaluating BRUKINSA in combination with venetoclax in treatment-naïve (TN) patients with high-risk chron.

BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024

BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA® (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region

DUBAI, United Arab Emirates--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, and NewBridge Pharmaceuticals have jointly decided to conclude their partnership. This strategic decision aligns with BeiGene's goals to expand its presence and directly manage operations in the MENA region. The collaboration between the two companies began in 2020 and included sales, distribution, and commercialization activities for BRUKINSA® (Zanubrutinib) in the MENA re.

BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA® (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region

BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the Company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 with a fireside chat at 1:20 pm EDT. Live webcast of this event can be accessed from the investors section of BeiGene's website at http://ir.beigene.com, https://hkexir.beigene.com/, https://sseir.beigene.com/. Archived replay will be available fo.

BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

7 Large-Cap Stocks That Can Jump 50% By 2025

The speed of growth of a given stock is much higher the smaller it is. Stock size is classified by market capitalization – current share price x number of shares outstanding – with large cap shares being above $10 billion.

7 Large-Cap Stocks That Can Jump 50% By 2025

BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL

SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of new analyses for BRUKINSA® (zanubrutinib) at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 - June 4, 2024. The presentations highlight analyses of the efficacy and safety of BRUKINSA compared to other Bruton's tyrosine kinase inhibitors (BTKis) used to treat chronic lymphocytic leukemia (CLL) and small lym.

Zacks Investment Research

BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why

Beigene's (BGNE) shares surge 32% in a month due to the label expansion of one of its key oncology drugs, Tevimbra, to treat three NSCLC indications, including first- and second-line use, in the EU.

BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why

See News Rankings